Background
NK or T cell-mediated cellular immunotherapy holds significant promise to successfully treat pediatric malignancy. In particular, genetically modified NK or T cells can mediate highly efficient and targeted clearance of tumor cells in young patients. Recent developments related to transduction of Chimeric Antigen Receptors (CARs) into NK or T cells have given us a renewed sense of optimism in the clinic.
